The DOI matches its Crossref record.
Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia
Abstract
COMMERCIAL concentrates of human antihemophilic factor (factor VIII) have been available for nearly 20 years and have resulted in dramatic changes in the treatment of classic hemophilia. Home therapy, surgical intervention, and prolonged treatment of hospitalized patients with hemophilia have all been facilitated by the availability of lyophilized factor VIII preparations.Although factor VIII concentrates have improved the ease and effectiveness of treatment, transfusion-associated complications have also increased. Patients with hemophilia have a high frequency of seropositivity for human immunodeficiency virus type 1 (HIV-1) and are at risk for the acquisition of the acquired immunodeficiency syndrome (AIDS). Most reports indicate . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molecular and Cellular Biology of Blood Coagulation
Flier, J. S., Underhill, L. H., Furie, B., & Furie, B. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261205 · Cited by 530
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Hoyer, L. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401063300108 · Cited by 361
Past, present and future of hemophilia: a narrative review
Franchini, M., & Mannucci, P. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-24 · Cited by 281
Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
Schwartz, R. S., Abildgaard, C. F., Aledort, L. M., Arkin, S., Bloom, A. L., Brackmann, H. H., Brettler, D. B., Fukui, H., Hilgartner, M. W., Inwood, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199012273232604 · Cited by 267
Metadata
- Authors
- White, G. C., McMillan, C. W., Kingdon, H. S., & Shoemaker, C. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1989-01-19
- Volume
- 320
- Issue
- 3
- Pages
- 166-170
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1987088922
- Cited by
- 164
- References
- 0
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia. https://app.cochat.ai/papers/10.1056/nejm198901193200307
- The paper
- White, G. C., McMillan, C. W., Kingdon, H. S., & Shoemaker, C. B. (1989). Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia. New England Journal of Medicine. https://doi.org/10.1056/nejm198901193200307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.